Identification of super-exhausted T cells: A novel population predictive of response to immunotherapy.

Authors

null

Florent Peyraud

Institut Bergonié, Bordeaux, France

Florent Peyraud , Jean-Philippe Guegan , Christophe Rey , Sophie Cousin , Guilhem Roubaud , Mathilde Cabart , Maxime Brunet , Ezogelin Oflazoglu Gruyters , Ariel Savina , Sylvestre Le Moulec , Bérangère Dadone-Montaudon , Fabrice Barlesi , Benjamin Besse , Yohann Loriot , Aurelien Marabelle , Jean-Charles Soria , Jean-Yves Scoazec , François Le Loarer , Alban Bessede , Antoine Italiano

Organizations

Institut Bergonié, Bordeaux, France, ImmuSmol, Bordeaux, France, Astra Zeneca, Rahway, NJ, Clinique Marzet, Pau, France, Centre Hospitalier Universitaire Nice, Nice, France, Gustave Roussy Cancer Campus, Villejuif, France

Research Funding

No funding received

Background: Given that most of cancer patients treated with anti-PD1/PD-L1 immune checkpoint blockers (ICB) do not derive benefit, there is a crucial need to identify reliable predictive biomarker of response. Besides PD-1, several key immune checkpoints, such as CTLA4, LAG3, TIM3 and TIGIT, are associated with a T cell exhausted phenotype and play a crucial role in leading to cancer immune evasion. The impact of simultaneous expression by T cells of distinct inhibitory receptors on outcome of patients treated with ICB is still unknown. Methods: We analyzed the tissue samples, collected before ICB initiation, from patients with solid tumors and included in an institutional molecular profiling program (NCT02534649). We used multiplexed-immunohistofluorescence with the following panel CD3/PD1/TIM3/LAG3/TIGIT/CTLA4, and performed immune cell characterization using multispectral images analysis. We then investigated the correlation between coexpression of T cell-associated exhaustion markers, clinical response rate, progression-free survival (PFS) and overall survival (OS) by Cox proportional hazards models. Results: Four hundred thirty five patients were included in the analysis (NSCLC: n=207, 47.6%; sarcoma: n=42, 9.7%; urothelial: n=30, 6.9%; others: n=156, 35.9%). Digital pathology analysis allowed us to identify a population of “super-exhausted” T cells characterized by the co-expression of PD1, LAG3, TIGIT and TIM3 which was enriched in 125 cases (28.7%), and was significantly associated with better PFS (HR 1.60, CI95 1.26-2.04, p<0.001) and OS (HR 1.42, CI95 1.07-1.89, p=0.016) in the whole cohort. Patients with super-exhausted high tumors had higher objective response rate (38.4%) compared to super-exhausted low tumors (19.7%, p<0.001). The presence of super-exhausted T cells was significantly higher in responders (10%) versus non responders (4%, p<0.001). Correlation with better outcome was observed whatever the subgroup considered (NSCLC vs other tumors, CD8 T cells density and presence of tertiary lymphoid structure [TLS]). In multivariate analysis (n=372, 85.5%), increased tumor infiltration by super-exhausted T cells (>1 %) was significantly associated with better PFS (HR 0.61, CI95 0.46-0.81, p<0.001, Table) and OS (HR 0.68, CI95 0.48-0.97, p=0.033, Table). Conclusions: The presence of super-exhausted T cells may represent a new predictive biomarker of response to ICB and pave the way for the development of effective ICB combinations. Data from an independent validation cohort will be presented at the meeting.

Patients
Endpoint
PFS
OS
372
Subgroup
HR
CI
p-value
HR
CI
p-value
Super Exhausted T cells (>1.09%)
0.61
(0.46-0.81)
<0.001
0.68
(0.48-0.97)
0.033
TLS positive
0.72
(0.56-0.94)
0.014
0.66
(0.48-0.90)
0.010
CD8 density (<152 cells/mm2)
1.11
(0.88-1.42)
0.74
1.06
(0.80-1.41)
0.69
Performance Status (>1)
1.60
(1.15-2.24)
0.006
2.19
(1.51-3.19)
<0.001

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics—Immunotherapy

Sub Track

PD1/PD-L1 Inhibitor Monotherapy

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 2596)

DOI

10.1200/JCO.2022.40.16_suppl.2596

Abstract #

2596

Poster Bd #

251

Abstract Disclosures

Similar Abstracts

Abstract

2024 ASCO Gastrointestinal Cancers Symposium

The combination of CD8 and TIM3 expression to predict survival outcomes in hepatocellular carcinoma.

First Author: Mitsuo Shimada

First Author: Robert Seager

First Author: Anastasia Xagara

First Author: YoungSam Park